Patent · US Active

Antibodies against human angiopoietin 2

US9109027B2 · kind B2 · utility

1Cited by

3References

2Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Ulrich Brinkmann · Weilheim, DE
Remko Albert Griep · Slemmestad, NO
Klaus Kaluza · Bad Heilbrunn, DE
Anita Kavlie · Oslo, NO
Christian Klein · Iffeldorf, DE
Joerg Thomas Regula · Munich, DE
Werner Scheuer · Penzberg, DE

Key dates

Filing date	Jul 13, 2012
Grant date	Aug 18, 2015
Priority date	—
Expiry date	May 1, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.